A study of GS-7977 and Ribavirin in patients who have hepatitis C and have received a liver transplant

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-002417-19

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To determine the antiviral efficacy of combination therapy with GS-7977 + ribavirin for 24 weeks in subjects with recurrent HCV post liver transplant as measured by sustained virologic response 12 weeks after discontinuation of therapy (SVR12 defined as HCV RNA < lower limit of quantitation [LLoQ] 12 weeks after last dose of study drug).


Critère d'inclusion

  • Recurrent Chronic HCV Post Liver Transplant